国际肿瘤学杂志

国际肿瘤学杂志 ›› 2015, Vol. 42 ›› Issue (2): 81-83.doi: 10.3760/cma.j.issn.1673-422X.2015.02.001

• 论著 •    下一篇

全身化疗同步全脑放疗治疗非小细胞肺癌脑转移的临床研究

王翔,张世强,张有为   

  1. 221009 徐州市中心医院肿瘤内科（王翔、张有为）;徐州市矿务局总医院放疗科(张世强)
  • 出版日期:2015-02-08 发布日期:2015-02-02
  • 通讯作者: 王翔 E-mail:thesky99@126.com
  • 基金资助:

    徐州市科技局课题(XM13B045)

Clinical research on systemic chemotherapy concurrent whole brain radiotherapy for brain metastases from nonsmall cell lung cancer

Wang Xiang, Zhang Shiqiang, Zhang Youwei   

  1. Department of Medical Oncology, Xuzhou Central Hospital, Xuzhou 221009, China
  • Online:2015-02-08 Published:2015-02-02
  • Contact: Wang Xiang E-mail:thesky99@126.com

PDF

1424

被引次数

4

摘要： 目的探讨全身化疗同步全脑放疗(WBRT)用于非小细胞肺癌（NSCLC）脑转移的可行性及安全性。方法80例NSCLC脑转移患者按随机数表法分为观察组和对照组各40例，分别给予全身化疗同步WBRT和全身化疗序贯WBRT。结果两组患者Ⅰ~Ⅳ度白细胞减少发生率分别为12.5%、25.0%、25.0%、0.0和30.0%、25.0%、12.5%、15.0%，差异有统计学意义（χ2=12.12，P＜0.05）。观察组的治疗总缓解率为20.0%（8/40），对照组为22.5%（9/40），差异无统计学意义（χ2=1.79，P＞0.05）。观察组中位无进展生存期为（3.5±2.3）个月，对照组为（3.6±1.1）个月，差异无统计学意义（t=5.23，P＞0.05）；观察组1年生存率为37.5%（15/40），显著高于对照组的17.5%（7/40），差异有统计学意义（χ2=9.11，P＜0.05）。结论全身化疗同步WBRT治疗NSCLC脑转移安全性较高，治疗效果好，具有较强的应用可行性。

关键词: 癌, 非小细胞肺, 肿瘤转移, 药物疗法, 全脑放疗

Abstract: ObjectiveTo explore the feasibility and safety of systemic chemotherapy concurrent whole brain radiotherapy (WBRT) for nonsmall cell lung cancer (NSCLC) with brain metastases. MethodsEighty cases of NSCLC patients with brain metastases were divided into observation group (40 cases) and the control group (40 cases) according to random number table. Patients were given systemic chemotherapy synchronous WBRT or sequential WBRT. ResultsThe ⅠⅣ degree leukocytopenia incidences of the two groups were 12.5%, 25.0%, 25.0%, 0.0 and 30.0%, 25.0%, 12.5%, 15.0%, and there was statistical significance (χ2=12.12, P<0.05). In the observation group, the total remission rate was 20% (8/40), and it was 22.5% (9/40) in the control group, with no significant difference (χ2=1.79, P>0.05). The median progression free survival of the observation group and of the control group were (3.5±2.3) months and (3.6±1.1) months, respectively, with no significant difference (t=5.23, P>0.05). But the 1years survival rate in the observation group was 37.5% (15/40), significantly higher than that in the control group (17.5%, 7/40), which had statistical significance (χ2=9.11, P<0.05). ConclusionThe safety of systemic chemotherapy synchronous WBRT for NSCLC patients with brain metastases is higher, with good curative effect and strong application feasibility.

Key words: Carcinoma, nonsmallcell lung, Neoplasm metastasis, Drug therapy, Whole brain radiotherapy